| INTRODUCTION
Current influenza vaccines afford only limited protection against antigenically drifted seasonal or against novel, pandemic influenza virus infection. Because of continuous antigenic changes of circulating influenza viruses, the seasonal influenza vaccine composition has to be updated regularly.
A significant advance in human infectious disease research would be the development of a new generation of influenza vaccines that induce a robust, broadly protective immune response, not only to drifted variants of seasonal influenza viruses, but preferably also to potential pandemic strains. Consequently, the development of such "universal" influenza vaccines has become a worldwide public health priority in both industrialised and low-and middle-income countries. 
| IMMUNOASSAYS

| Haemagglutination inhibition and single-radial haemolysis assays
The immune response induced by influenza vaccines has been measured traditionally by three classical immunoassays: haemagglutination inhibition (HI), single-radial haemolysis (SRH) and virus neutralisation (VN) assays. The HI assay detects antibodies that bind to the viral haemagglutinin and prevent the virus-mediated agglutination of erythrocytes. There is a consensus, although not universally accepted, that an HI antibody titre of 40 correlates with a 50% reduction in the risk of contracting influenza 1 . This correlate of protection has been established from studies in healthy adults and is not appropriate for children 2 . The HI assay faces various technical challenges, such as variations when using erythrocytes from different species and variability between batches of erythrocytes from the same species. The antibody titres measured by HI and VN assays usually correlate somewhat for seasonal influenza viruses, but correlation may not be observed when testing non-human subtypes such as H5N1 viruses.
The SRH assay measures antibodies that bind to the influenza virus and fix complement (usually guinea pig complement) 3, 4 . The SRH assay displays higher sensitivity for H5N1 viruses than the HI assay and has been shown to be relatively reproducible between laboratories. A correlate of protection has also been defined for SRH, that is a zone of 25 mm 2 5 . While correlates of protection have been widely used for the HI and SRH assays, their relevance has been questioned and they are not valid in Europe any more 6 .
| Virus neutralisation assay
Neutralising antibodies are generally accepted as primary mediators of immunity against influenza virus 7 . The VN assay mainly detects functional antibodies that bind the HA globular head and block receptor binding but can also measure antibodies that block entry at the stage of membrane fusion. There are various formats of the VN assay (Table 1) .
Collaborative studies have shown that interlaboratory variability of VN assays can be considerable; the use of antibody standards can reduce it 8 ; however, antibody standards are not usually available for influenza serology studies.
As opposed to the HI assay, no correlate of protection has been established for the VN assay. In a recent household transmission study, microneutralisation titres ≥ 40 were associated with 49% protection against H3N2 infection 9 .
As the three main serologic assays HI, VN and SRH detect different populations of antibodies, different degrees of correlation between these assays can be observed. 
| Automated imaging of hemagglutination assays
| APPROACHES FOR THE EVALUATION OF ANTIBODY-MEDIATED ENHANCED INFECTION
Some 
| Influenza antibody profiling by protein microarray
An alternative approach to current serological assays is the use of protein microarrays that can simultaneously measure antibody re- against H9 were also detected in some sera in this study even though it is unlikely these subjects would have been naturally exposed 15 . This is perhaps due to the increasing breadth of antibodies made against conserved epitopes over a person's lifetime that can cross-react with multiple subtypes. Whether these antibodies offer any protection remains to be determined.
Future work should include more comparative experiments between the protein array and biological assays to assess the functional relevance of the protein array data. Alternative anti-NA serological assays, in addition to the established TBA and ELLA methods, are presented in Table 2 . 
| MEASUREMENT OF ANTINEURAMINIDASE INHIBITION TITRES BY ENZYME-LINKED LECTIN ASSAY
| ROLE OF T AND B CELLS IN RESPONSE TO INFLUENZA VACCINES
| ELISpot
The Although the ELISpot assay performance is straightforward, there are a number of variables that must be considered for assay standardisation both within and between laboratories, for example peripheral blood mononuclear cell (PBMC) preparation procedures, reagents, incubation periods and the stimulating antigen used. It is also necessary to use clinical trial data and human subjects in order to ascertain correlates of protection.
| Intracellular cytokine staining assay
The intracellular cytokine staining (ICS) assay can be used to evaluate T-cell immunity and correlates of protection for influenza vaccines.
This assay is currently being standardised through the European
Union funded UNISEC project.
The ICS assay measures multiple cytokines and lymphocyte sub- In the ICS assay, common peptides between subtypes could be used to measure potential universality. Currently, most available peptide pools for influenza are optimised for CD8, rather than CD4 cells.
With regard to standardisation, there is an element of subjectivity introduced by the operator when analysing flow cytometry data, for example the positioning of the gates around the cell populations of interest. This may warrant an automated analysis process.
Seeing as the influenza virus infects the lungs and that a nonhighly pathogenic influenza virus does not spread into the blood, it was suggested that it may be valuable to measure early responding T cells in the lungs rather than or in addition to PBMCs. Measuring CTLs also produce cytokines such as IFNγ and TNFα. A summary of established CTL assays is presented in Table 3 .
| Antibody-dependent cellular cytotoxicity assay
The antibody-dependent cellular cytotoxicity (ADCC) assay is a rel- 
| Antibody-dependent respiratory burst assay
Antibody-dependent respiratory burst (ADRB) assay is an assay to measure the combined (antiviral) effects of antibodies and neutrophils 28 . The assay was first described for malaria and was well correlated with protection 28 . The ADRB assay is a relatively simple technique to assess antibody functionality (similar to ADCC) requiring only luminescence equipment. The ADRB assay can be performed in high throughput, and it can be standardised. Two potential assay setups 29 are described in Table 5 .
The relevance of the ADRB for influenza is still being explored, and a number of issues remain to be investigated; these include the following: correlations between formats using plate-bound antigen Proficiency testing and external quality assessment are important for the evaluation of the process of harmonisation and standardisation. Testing a laboratory's quality system with samples of known, but undisclosed content will give an overview of the laboratory's performance and will provide a comparison with that of other laboratories.
A clear need for further collaboration, networking and international communication regarding the harmonisation of immuno-assays was identified, and CONSISE could be the venue for these activities.
The standardisation should be initiated early, before methods drift too much. The European-American partnership established during the organisation of this workshop was recognised as a clear asset in this direction and will be sustained.
